Jeremy Grantham's MRK Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 6.63 M shares of Merck & Co., Inc. (MRK) worth $556.07 M, representing 1.57% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 49 quarters.
Based on 13F filings since 2013, Jeremy Grantham has maintained a long-term strategic position in MRK, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2018, adding 2.39 M shares. Largest reduction occurred in Q1 2014, reducing 7.49 M shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Merck & Co (MRK) Holding Value Over Time
Track share changes against reported price movement
Quarterly Merck & Co (MRK) Trades by Jeremy Grantham
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +13.57 M | Add 0.00% | 13.57 M | $44.32 |
| Q3 2013 | +359,443 | Add 2.65% | 13.93 M | $45.43 |
| Q4 2013 | -3.8 M | Reduce 27.28% | 10.13 M | $47.76 |
| Q1 2014 | -7.49 M | Reduce 73.94% | 2.64 M | $54.17 |
| Q2 2014 | -2.28 M | Reduce 86.46% | 357,338 | $55.20 |
| Q3 2014 | -232,741 | Reduce 65.13% | 124,597 | $56.57 |
| Q4 2014 | -110,950 | Reduce 89.05% | 13,647 | $54.22 |
| Q1 2015 | -4,297 | Reduce 31.49% | 9,350 | $54.87 |
| Q2 2015 | -2,538 | Reduce 27.14% | 6,812 | $54.32 |
| Q3 2015 | -2,410 | Reduce 35.38% | 4,402 | $47.02 |
| Q1 2016 | -4,402 | Sold Out | 0 | $0.00 |
| Q3 2016 | +7,860 | New Buy | 7,860 | $59.54 |
| Q4 2016 | +6,498 | Add 82.67% | 14,358 | $56.21 |
| Q1 2017 | -6,393 | Reduce 44.53% | 7,965 | $60.64 |
| Q2 2017 | -1,363 | Reduce 17.11% | 6,602 | $61.19 |
| Q3 2017 | +71,788 | Add 1087.37% | 78,390 | $61.09 |
| Q4 2017 | +440,546 | Add 561.99% | 518,936 | $53.69 |
| Q1 2018 | +2.39 M | Add 460.38% | 2.91 M | $51.98 |
| Q2 2018 | +1.21 M | Add 41.76% | 4.12 M | $57.92 |
| Q3 2018 | +41,407 | Add 1.00% | 4.16 M | $67.69 |
| Q4 2018 | -443,770 | Reduce 10.66% | 3.72 M | $72.91 |
| Q1 2019 | -491,013 | Reduce 13.20% | 3.23 M | $79.36 |
| Q2 2019 | +669,806 | Add 20.74% | 3.9 M | $80.01 |
| Q3 2019 | +200,953 | Add 5.15% | 4.1 M | $80.32 |
| Q4 2019 | -78,569 | Reduce 1.92% | 4.02 M | $86.78 |
| Q1 2020 | -827,734 | Reduce 20.58% | 3.19 M | $73.42 |
| Q2 2020 | -91,698 | Reduce 2.87% | 3.1 M | $73.79 |
| Q3 2020 | +57,703 | Add 1.86% | 3.16 M | $79.15 |
| Q4 2020 | +12,530 | Add 0.40% | 3.17 M | $78.05 |
| Q1 2021 | +266,258 | Add 8.39% | 3.44 M | $73.56 |
| Q2 2021 | +133,722 | Add 3.89% | 3.57 M | $77.77 |
| Q3 2021 | +138,334 | Add 3.87% | 3.71 M | $75.11 |
| Q4 2021 | +77,162 | Add 2.08% | 3.79 M | $76.64 |
| Q1 2022 | +59,929 | Add 1.58% | 3.85 M | $82.05 |
| Q2 2022 | -737,348 | Reduce 19.17% | 3.11 M | $91.17 |
| Q3 2022 | -3,300 | Reduce 0.11% | 3.11 M | $86.12 |
| Q4 2022 | +36,156 | Add 1.16% | 3.14 M | $110.95 |
| Q1 2023 | -89,264 | Reduce 2.84% | 3.05 M | $106.39 |
| Q2 2023 | +564,296 | Add 18.48% | 3.62 M | $115.39 |
| Q3 2023 | +411,073 | Add 11.36% | 4.03 M | $102.95 |
| Q4 2023 | -3,058 | Reduce 0.08% | 4.03 M | $109.02 |
| Q1 2024 | +701,200 | Add 17.42% | 4.73 M | $131.95 |
| Q2 2024 | +601,234 | Add 12.72% | 5.33 M | $123.80 |
| Q3 2024 | +583,752 | Add 10.96% | 5.91 M | $113.56 |
| Q4 2024 | +253,227 | Add 4.28% | 6.17 M | $99.48 |
| Q1 2025 | +521,325 | Add 8.46% | 6.69 M | $89.76 |
| Q2 2025 | -217,023 | Reduce 3.25% | 6.47 M | $79.16 |
| Q3 2025 | +155,777 | Add 2.41% | 6.63 M | $83.93 |
Jeremy Grantham's Merck & Co Investment FAQs
Jeremy Grantham first purchased Merck & Co., Inc. (MRK) in Q2 2013, acquiring 13,569,638 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Merck & Co., Inc. (MRK) for 49 quarters since Q2 2013.
Jeremy Grantham's largest addition to Merck & Co., Inc. (MRK) was in Q2 2013, adding 13,569,638 shares worth $601.44 M.
According to the latest 13F filing for Q3 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 6,625,350 shares of Merck & Co., Inc. (MRK), valued at approximately $556.07 M.
As of the Q3 2025 filing, Merck & Co., Inc. (MRK) represents approximately 1.57% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.
Jeremy Grantham's peak holding in Merck & Co., Inc. (MRK) was 13,929,081 shares, as reported at the end of Q3 2013.